ANTITUBERCULOUS ACTION OF A NEW ANTIBIOTIC, LIVIDOMYCIN
新抗生物質Lividomycinの抗結核菌作川

Michio TSUKANIURA, Shoji MIZUNO, Masahiko YAMAMOTO
1970 Kekkaku (Tuberculosis)  
In vitro and in vivo experimental studies were carried out on the antituberculous action of a new antibiotic, Lividomycin, discovered by the Kowa Company, Nagoya. Mycobacterium tuberculosis H37R, and Aoyama-B and tubercle bacilli recently isolated from sputa of patients were used in the study. The antibiotic is produced by Streptomyces lividus n. sp. and has a molecular formula C29H55N5018 belonging to the aminocyclitol group. Estimation of susceptibility (or drug resistance level) was carried
more » ... ut by the "actual count method"')-3), using the Ogawa egg medium. The composition of the medium was as follows : Basic solution (1% KH2PO4 and 1% sodium glutamate), 100 m/ ; Whole eggs, 200 m/ ; Glycerol, 6 ml; malachite green solution, 6 ml. The medium was poured in 8 ml quantities into tubes and made as slopes by sterilization at 90'C for 60 minutes. Antituberculous agents were added to the medium before sterilization and the concentration of the agents was expressed as the concentration added itself. (Remark. The activity of kanamycin in the Ogawa egg medium was reduced to 25% when compared with that in the LOwenstein-Jensen medium.) The resistance degree by the actual count method was read as the highest concentration of drug on which a small inoculum, consisting of 20 to 100 viable units, was able to grow after incubation at 37°C for 4 weeks (or, in some cases, for 3 weeks). 結 結 第45巻 第8号 Tubercle bacilli isolated from patients, which were resistant to 500pg1m1 or more kanamycin, were resistant to lividomycin, whereas the tubercle bacilli, which were resistant to 200pg/ml or less kanamycin, were susceptible to lividomycin (Table 2 ). The level of kanamycin resistance in tubercle bacilli from patients was closely related to the development of lividomycin resistance. Tubercle bacilli resistant to capreomycin were resistant to lividomycin, as well (Table 2 ). Tubercle bacilli resistant to all other drugs, streptomycin, isoniazid, p-aminosalicylate, ethambutol, ethionamide and cycloserine, were susceptible to lividomycin. 3. Cross resistance in M. tuberculosis H87Rv and Aoyama-B Kanamycin-resistant strains and capreomycin-resistant strains were resistant to lividomycin. Strains resistant to the other drugs remained susceptible to lividomycin (Table 1 ). Lividomycin-resistant strains were resistant to kanamycin, capreomycin and, to a less extent, to streptomycin (Tables 5 and 6 ). Lividomycin-resistant strain isolated from the H17Rv strain was susceptible to viomycin, but that from the Aoyama-B strain was resistant to it. In conclusion, there is a "two way"-cross resistance relationship between lividomycin and kanamycin as well as between lividomycin and capreomycin. There is a "one way"-cross resistance relationship between lividomycin and streptomycin (Tables 1, 5 and 6 ). Development of lividomycin resistance in M. tuberculosis Spontaneously lividomycin-resistant mutants were found in the H37Rv and Aoyama-B strains at rates of 10-5 to 10-6. The mutants grew very slowly on the primary isolation medium and the colonies of the mutants appeared as late as after incubation for 8 weeks. However, if transferred to fresh medium, these mutants could grow at a normal growth rate (Table 4 ) . 5. Bacteriostatic action on the mycobacteria other than M. tuberculosis
doi:10.11400/kekkaku1923.45.8_263 fatcat:qyazm2yconf2zbg5rdrea5b7eq